This activity is supported by an independent educational grant from Amicus.
Determining whether treatment continues to provide benefit requires a structured, individualized assessment. In this module Prof. Tahseen Mozaffar explores how the European Pompe Consortium's start, switch, and stop framework can support treatment reassessment, alongside shared decision-making, supportive care, and ongoing monitoring of response.
Session highlights
- Apply structured reassessment criteria to determine whether treatment has stabilized or improved skeletal and respiratory function.
- Understand the options for ERT by considering the evidence, treatment history, safety, burden, and individual patient circumstances.
- Make treatment decisions collaboratively by incorporating patient goals, preferences, and acceptable treatment burden alongside the available evidence.
- Define and monitor response by agreeing measurable outcomes, documenting the plan, and establishing clear timepoints for reassessment.
This is Module Three of Three, find Modules One and Two here.
Who Should Participate
This program is designed for healthcare practitioners treating adults with Late-Onset Pompe Disease (LOPD), including:
- Primary Care Leads: Including neuromuscular specialists, neurologists, and metabolic disease specialists involved in direct monitoring, ongoing treatment, and disease management.
- Multidisciplinary Team Members: Including pulmonologists/respiratory physicians, geneticists, genetic counselors, rehabilitation specialists, advanced practice providers (NPs/PAs), and neuromuscular nurses involved in comprehensive LOPD care.
Prefer to read? See our Key Clinical Summary Here.
Faculty
Professor Tahseen Mozaffar, MD
Tahseen Mozaffar, MD, is a board-certified neurologist and Director of the UCI Health ALS & Neuromuscular Center. He earned his medical degree from Aga Khan University. Specializing in amyotrophic lateral sclerosis (ALS), myasthenia gravis, Pompe disease, and rare muscular dystrophies, Dr. Mozaffar leads extensive clinical and translational research as the principal investigator for over a dozen trials and lead UCI investigator for the NINDS-supported NeuroNEXT network. A prolific researcher with more than 175 peer-reviewed publications, he serves as an NIH reviewer and consultant for global pharmaceutical companies on trial design and safety monitoring in rare neuromuscular diseases
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Tahseen Mozaffar has the following relevant financial relationships: Amicus: Consulting, Research Funding; Aro Bio: Research Funding; Denali: Consulting, Research Funding; Regeneron: Consulting; Sanofi: Consulting, Research Funding; Shionogi: Consulting and Research Funding.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 26th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting October 13th 2026, and will expire on October 26th 2027.
Estimated time to complete this activity: 15 Minutes